Insilico Medicine Hong Kong Limited
We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development.
See below for the Latest Insilico Medicine Hong Kong Limited News, Analysis, Profit Results, Share Price Information, and Commentary.
AI-driven drug discovery company Insilico Medicine Hong Kong Limited clinches an award at the HKB Technology Excellence Awards
AI-driven drug discovery company Insilico Medicine Hong Kong Limited clinches an award at the HKB Technology Excellence Awards
It has been delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, and ageing-related diseases.
Commentary
Hong Kong hospitality: Momentum and the new lifestyle era
Understanding Hong Kong’s new land premium policy
Hong Kong: At the forefront of digitalisation and evolving international disputes
AI drug discovery, GLP-1, and the next wave of Hong Kong biotech listings